Redefining Colorectal Cancer by Tumor Biology
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Colorectal cancer treatment has undergone a paradigm shift. We no longer see this disease as a singular, anatomic tumor type but rather a set of disease subgroups. Largely because of a better understanding of cancer biology and the introduction and integration of molecular biomarkers—the premise of precision therapy—we are beginning to direct treatments toward the right tumor target(s) in the right patients. The field of molecular profiling is continually evolving, and new biomarkers are constantly being discovered that have investigational, therapeutic, and/or prognostic implications—negative or positive. To date, only a few biomarkers have sufficient actionable, clinical implication to earn international guideline-recommended routine testing. Hence, it is vital that the treating oncologist should know which biomarkers to assess, when in the treatment course to test for them, and how the test is to be done. Correct interpretation of profiling results is imperative. Herein, we focus on international guideline-recommended mutation testing for patients prior to their colorectal cancer treatment initiation. The clinical applications of circulating tumor DNA (ctDNA) in patients with metastatic disease, based on our current knowledge and capabilities, are also addressed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Molecular testing for activating KRAS and NRAS mutations (comprehensive RAS panel) and BRAF mutations is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to select patients for anti-EGFR therapy [23].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [23]
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., Herman, G. E., Hufnagel, S. B., Klein, T. E., Korf, B. R., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.190 · Cited by 1,644
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citationEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H., Knudsen, M., Nordentoft, I., Wu, H.-T., Tin, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0528 · Cited by 1,011
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3616 · Cited by 668
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., Tacey, M., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 635
Self-citationMicrosatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Latham, A., Srinivasan, P., Kemel, Y., Shia, J., Bandlamudi, C., Mandelker, D., Middha, S., Hechtman, J., Zehir, A., Dubard-Gault, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00283 · Cited by 616
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., Tusquets, I., Albanell, J., Rodon, J., Tabernero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0531-8 · Cited by 519
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513
Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., & Stroun, M. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04828.x · Cited by 414
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival
Phipps, A. I., Limburg, P. J., Baron, J. A., Burnett-Hartman, A. N., Weisenberger, D. J., Laird, P. W., Sinicrope, F. A., Rosty, C., Buchanan, D. D., Potter, J. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.038 · Cited by 401
Microsatellite Instability Detection by Next Generation Sequencing
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.223677 · Cited by 399
Stoffel, E. M., Mangu, P. B., Gruber, S. B., Hamilton, S. R., Kalady, M. F., Lau, M. W. Y., Lu, K. H., Roach, N., & Limburg, P. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1322 · Cited by 373
Brannon, A., Vakiani, E., Sylvester, B. E., Scott, S. N., McDermott, G., Shah, R. H., Kania, K., Viale, A., Oschwald, D. M., Vacic, V., et al. (2014) · Genome Biology · doi:10.1186/preaccept-1207406452128377 · Cited by 372
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Vidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Schrader, K. A., Cheng, D. T., Joseph, V., Prasad, M., Walsh, M., Zehir, A., Ni, A., Thomas, T., Benayed, R., Ashraf, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5208 · Cited by 339
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D'Angelica, M., Viale, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 282
Lynch Syndrome–Associated Colorectal Cancer
Sinicrope, F. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1714533 · Cited by 279
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
Morelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar, E., Johnson, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 253
Garlan, F., Laurent-Puig, P., Sefrioui, D., Siauve, N., Didelot, A., Sarafan-Vasseur, N., Michel, P., Perkins, G., Mulot, C., Blons, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3155 · Cited by 250
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 244
Dienstmann, R., Mason, M. J., Sinicrope, F. A., Phipps, A. I., Tejpar, S., Nesbakken, A., Danielsen, S. A., Sveen, A., Buchanan, D. D., Clendenning, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx052 · Cited by 237
Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R., Segal, N. H., Varghese, A. M., Reidy-Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 234
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Self-citationAn analysis of genetic heterogeneity in untreated cancers
Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0185-x · Cited by 209
Rubenstein, J. H., Enns, R., Heidelbaugh, J., Barkun, A., Adams, M. A., Dorn, S. D., Dudley-Brown, S. L., Flamm, S. L., Gellad, Z. F., Gruss, C. B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.036 · Cited by 204
Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A. M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw018 · Cited by 195
Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J. M., Paéz, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187
Bachet, J. B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M. L., Meurisse, A., Normand, C., Gornet, J. M., Artru, P., Louafi, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy061 · Cited by 178
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
Hampel, H., Pearlman, R., Beightol, M., Zhao, W., Jones, D., Frankel, W. L., Goodfellow, P. J., Yilmaz, A., Miller, K., Bacher, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0104 · Cited by 172
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Sartore-Bianchi, A., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 171
Cocco, E., Benhamida, J., Middha, S., Zehir, A., Mullaney, K., Shia, J., Yaeger, R., Zhang, L., Wong, D., Villafania, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3126 · Cited by 163
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Clancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 133
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Normanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 119
Biomarker concordance between primary colorectal cancer and its metastases
Bhullar, D. S., Barriuso, J., Mullamitha, S., Saunders, M. P., O'Dwyer, S. T., & Aziz, O. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.050 · Cited by 115
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 111
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0311 · Cited by 102
Molecular targeted therapy of BRAF-mutant colorectal cancer
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 100
Thierry, A. R., Pastor, B., Jiang, Z.-Q., Katsiampoura, A. D., Parseghian, C., Loree, J. M., Overman, M. J., Sanchez, C., Messaoudi, S. E., Ychou, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0232 · Cited by 97
Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 97
Cohen, R., Buhard, O., Cervera, P., Hain, É., Dumont, S., Bardier–Dupas, A., Bachet, J., Gornet, J., López‐Trabada, D., Dumont, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.022 · Cited by 93
Strickler, J. H., Zemla, T., Ou, F.-S., Cercek, A., Wu, C., Sanchez, F. A., Hubbard, J., Jaszewski, B., Bandel, L., Schweitzer, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz246.005 · Cited by 92
García‐Foncillas, J., Tabernero, J. M., Élez, E., Aranda, E., Benavides, M., Camps, C., Lewintre, E. J., López‐López, R., Muinelo‐Romay, L., Montagut, C. O., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0293-5 · Cited by 89
Hazar-Rethinam, M., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 75
Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2017) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 74
Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)
Millington, G. W. M. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12015 · Cited by 69
Charlton, M. E., Kahl, A. R., Greenbaum, A. A., Karlitz, J. J., Lin, C. H., Lynch, C. F., & Chen, V. W. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7011 · Cited by 64
Gomez‐Roca, C., Delord, J., Robert, C., Hidalgo, M. M., von Moos, R., Arance, A. M., Élez, E., Michel, D., Seroutou, A., Demuth, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.38 · Cited by 52
Meiri, E., Garrett-Mayer, E., Halabi, S., Mangat, P. K., Shrestha, S., Ahn, E. R., Osayameh, O., Perla, V., & Schilsky, R. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.133 · Cited by 52
Oncologist use and perception of large panel next-generation tumor sequencing
Schram, A. M., Reales, D. N., Galle, J., Cambria, R., Durany, R., Feldman, D. R., Sherman, E. J., Rosenberg, J. E., D’Andrea, G. M., Baxi, S. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx294 · Cited by 44
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
Bregni, G., Sciallero, S., & Sobrero, A. F. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7229 · Cited by 44
How I treat MSI cancers with advanced disease
Kok, M., Chalabi, M., & Haanen, J. B. A. G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000511 · Cited by 39
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 37
Self-citationMSI-H: a truly agnostic biomarker?
Sidaway, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0310-5 · Cited by 27
Kopetz, S., Grothey, A. A., Cutsem, E. V., Yaeger, R. D., Wasan, H. S., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A. M., Maharry, K. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz183.004 · Cited by 24
Klute, K. A., Garrett-Mayer, E. S., Halabi, S., Mangat, P. K., Nazemzadeh, R., Yost, K. J., Butler, N. L., Perla, V., & Schilsky, R. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.122 · Cited by 16
Physician interpretation of genomic test results and treatment selection
Brusco, L., Wathoo, C., Shaw, K. R. M., Holla, V. R., Bailey, A. M., Johnson, A. M., Khotskaya, Y. B., Litzenburger, B. C., Sánchez, N., Zeng, J., et al. (2017) · Cancer · doi:10.1002/cncr.31112 · Cited by 12
Optimizing Anti-EGFR Therapy in Colorectal Cancer
Salazar, R., & Ciardiello, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1768 · Cited by 11
Cremolini, C., Antoniotti, C., Lonardi, S., Rossini, D., Morano, F., Cordio, S. S., Bergamo, F., Marmorino, F., Maiello, E., Passardi, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz183.005 · Cited by 7
Research works printed but not linked: 12
- Gutierrez ME, 2019, Precision Oncol, 3, 1
- Gupta R, 2020, J Clin Oncol, 38
- Pennell NA, 2019, Precision Oncol, 3, 1
- 10.1186/s13059-014-0454-7 · doi:10.1186/s13059-014-0454-7 · Paper page
- Mandel P, 1948, C R Seances Soc Biol Fil, 142, 241
- Sorenson GD, 1994, Cancer Epidemiol Biomarkers Prev, 3, 67
- Battaglin F, 2018, Clin Adv Hematol Oncol, 16, 735
- Thomas J, Clin Colorectal Cancer
- Lenz H-J, 2019, J Clin Oncol, 37
- Kopetz S, 2017, J Clin Oncol, 35
- Nakamura Y, 2019, Ann Oncol, 30, v198
- Sartore-Bianchi A, 2019, Ann Oncol, 30, v851
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“…European Society for Medical Oncology (ESMO) to select patients for anti-EGFR 3 of 19 (comprehensive RAS panel) and BRAF mutations is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to select patients for anti-EGFR therapy [23].”
BackgroundDuffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 65
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 42
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Metadata
- Authors
- Salem, M. E., Puccini, A., & Tie, J.
- Affiliations
- Levine Cancer Institute (US)
- Ospedale Policlinico San Martino (IT)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Salem, Mohamed E.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2020-05
- Volume
- 40
- Issue
- 40
- Pages
- 147-159
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W3012562659
- Cited by
- 14
- References
- 108
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 2
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, molecular biomarkers, precision oncology, molecular profiling, mutation testing, circulating tumor DNA, metastatic colorectal cancer, tumor subtypes, prognostic factors, actionable biomarkers
- MeSH terms
- Biology, Female, Humans, Male, Prognosis, Colorectal Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.